Document is current

Article History

Received: 27 August 2018

Accepted: 29 November 2018

First Online: 7 December 2018

Ethics approval and consent to participate

: Prior to inclusion, informed consent was obtained from each patient. All were included into the study by one of the authors (LR). All asked were alert (RLS 1; [CitationRef removed]) and without impressive aphasia. In all cases, consent was obtained directly from the patient. In many cases the patient conferred with family members but they were never advised to decline participation. Patients were informed by verbal and written information and consent was given in verbal form, because at the time for ethical approval (15th of April 1992) the ethical committee did not yet require written consent or raise the question. The criteria were approved by the Gothenburg Regional Ethics Committee (Dnr 172–92), Sweden.

: Not applicable.

: HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, has served at advisory boards of Eli Lilly, Roche Diagnostics, Wave, Samumed and CogRx and has received travel support from TEVA.KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.Other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.